CAS 2252334-12-4

Epitinib succinate

CAS : 2252334-12-4

Epitinib succinate

Degré de pureté : ≥95%

Masse moléculaire : 548.59g/mol

Ref: 54-BUP02563

Epitinib succinate

CAS : 2252334-12-4

Epitinib succinate is a potent and selective inhibitor of human epidermal growth factor receptor (EGFR) tyrosine kinase, which is overexpressed in many types of cancer. This Chinese analog of the anticancer drug Gefitinib has been shown to inhibit tumor growth and induce apoptosis in cancer cells. Epitinib succinate selectively inhibits EGFR kinases by binding to the ATP-binding site, leading to inhibition of downstream signaling pathways that promote cell proliferation and survival. This drug has been tested in preclinical studies and has shown promising results as a potential treatment for various types of cancer. Epitinib succinate can be detected in urine and is currently being investigated as a potential toxin for targeted cancer therapy.

Formule : C₂₈H₃₂N₆O₆

Degré de pureté : Min. 95%

Masse moléculaire : 548.6 g/mol

Ref: 3D-CQD33412

Epitinib succinate

CAS : 2252334-12-4

Epitinib succinate (HMPL-813 succinate) is an orally active and brain penetration EGFR tyrosine kinase inhibitor and can be used in studies about cancer.

Formule : C₂₈H₃₂N₆O₆

Degré de pureté : 98.02% - 99.79%

Couleur et forme : Solid

Masse moléculaire : 548.59

Ref: TM-T35914